Literature DB >> 11114101

Diabetic neuropathy--a continuing enigma.

K Sugimoto1, Y Murakawa, A A Sima.   

Abstract

In this article we will review the clinical signs and symptoms of diabetic somatic polyneuropathy (DPN), its prevalence and clinical management. Staging and classification of DPN will be exemplified by various staging paradigms of varied sophistication. The results of therapeutic clinical trials will be summarized. The pathogenesis of diabetic neuropathy reviews an extremely complex issue that is still not fully understood. Various recent advances in the understanding of the disease will be discussed, particularly with respect to the differences between neuropathy in the two major types of diabetes. The neuropathology and natural history of diabetic neuropathy will be discussed pointing out the heterogeneities of the disease. Finally, the various prospective therapeutic avenues will be dealt with and discussed. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 11114101     DOI: 10.1002/1520-7560(200011/12)16:6<408::aid-dmrr158>3.0.co;2-r

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  35 in total

Review 1.  Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy.

Authors:  Megan Jack; Douglas Wright
Journal:  Transl Res       Date:  2012-01-10       Impact factor: 7.012

Review 2.  Early diabetic neuropathy: triggers and mechanisms.

Authors:  Maxim Dobretsov; Dmitry Romanovsky; Joseph R Stimers
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

Review 3.  Neuropathy in prediabetes: does the clock start ticking early?

Authors:  Nikolaos Papanas; Aaron I Vinik; Dan Ziegler
Journal:  Nat Rev Endocrinol       Date:  2011-07-12       Impact factor: 43.330

4.  Dihydroprogesterone increases the gene expression of myelin basic protein in spinal cord of diabetic rats.

Authors:  Marzia Pesaresi; Silvia Giatti; Donato Calabrese; Omar Maschi; Donatella Caruso; Roberto Cosimo Melcangi
Journal:  J Mol Neurosci       Date:  2010-03-27       Impact factor: 3.444

5.  Intra-axonal recording from large sensory myelinated axons: demonstration of impaired membrane conductances in early experimental diabetes.

Authors:  Jasna Kriz; Ante L Padjen
Journal:  Diabetologia       Date:  2003-02-18       Impact factor: 10.122

6.  Blocking mitochondrial calcium release in Schwann cells prevents demyelinating neuropathies.

Authors:  Sergio Gonzalez; Jade Berthelot; Jennifer Jiner; Claire Perrin-Tricaud; Ruani Fernando; Roman Chrast; Guy Lenaers; Nicolas Tricaud
Journal:  J Clin Invest       Date:  2016-02-15       Impact factor: 14.808

7.  Diabetes-induced myelin abnormalities are associated with an altered lipid pattern: protective effects of LXR activation.

Authors:  Gaia Cermenati; Federico Abbiati; Solei Cermenati; Elisabetta Brioschi; Alessandro Volonterio; Guido Cavaletti; Enrique Saez; Emma De Fabiani; Maurizio Crestani; Luis M Garcia-Segura; Roberto C Melcangi; Donatella Caruso; Nico Mitro
Journal:  J Lipid Res       Date:  2011-12-07       Impact factor: 5.922

Review 8.  Immunotherapy for diabetic amyotrophy.

Authors:  Yee Cheun Chan; Yew Long Lo; Edwin Sy Chan
Journal:  Cochrane Database Syst Rev       Date:  2017-07-26

9.  Global transcriptional programs in peripheral nerve endoneurium and DRG are resistant to the onset of type 1 diabetic neuropathy in Ins2 mice.

Authors:  Anne-Sophie de Preux Charles; Valérie Verdier; Jennifer Zenker; Bastian Peter; Jean-Jacques Médard; Thierry Kuntzer; Jacques S Beckmann; Sven Bergmann; Roman Chrast
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

Review 10.  Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data.

Authors:  Anders A F Sima
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.